Form 8-K - Current report:
SEC Accession No. 0001437749-24-027383
Filing Date
2024-08-20
Accepted
2024-08-20 16:38:59
Documents
14
Period of Report
2024-08-14
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 FORM 8-K nrxp20240820_8k.htm   iXBRL 8-K 24880
  Complete submission text file 0001437749-24-027383.txt   176024

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA nxrp-20240814.xsd EX-101.SCH 3871
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nxrp-20240814_def.xml EX-101.DEF 13796
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE nxrp-20240814_lab.xml EX-101.LAB 18158
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nxrp-20240814_pre.xml EX-101.PRE 13828
16 EXTRACTED XBRL INSTANCE DOCUMENT nrxp20240820_8k_htm.xml XML 4834
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

EIN.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38302 | Film No.: 241225775
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)